Loading…
Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase
Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active fo...
Saved in:
Published in: | Biomolecular NMR assignments 2015-04, Vol.9 (1), p.15-19 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493 |
container_end_page | 19 |
container_issue | 1 |
container_start_page | 15 |
container_title | Biomolecular NMR assignments |
container_volume | 9 |
creator | Mosulén, Silvia Pineda-Lucena, Antonio Carbajo, Rodrigo J. |
description | Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the
1
H,
13
C and
15
N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme. |
doi_str_mv | 10.1007/s12104-013-9536-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661333591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3615679541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</originalsourceid><addsrcrecordid>eNp1kU2LFDEQhoMo7rr6A7xIwIuX1lTSnY-jDOsHLHhR8NZk0pXpXqaTMdUR9t_b7ayLCJ4SyPO-Keph7CWItyCEeUcgQbSNANW4TunGPWKXYE3bSCO-P364g71gz4huhdBSSHjKLmSrXAedvmR3uxHnKfgjp3GKC_dE0yHNmBbiPg2cMOQ0-HLHaSk1LLUgz5EvI3KqpeSDX5APefZT4jEXPpR64MNEIf_E36E6TEhbZKyzT3zEky8-ecLn7En0R8IX9-cV-_bh-uvuU3Pz5ePn3fubJijXLo0Ug3G-w9AGES2Ci65VcR-1lNo4YRXovQ3OR9WBAY0yWqE0BtsZaWzr1BV7c-49lfyjIi39vI6Hx6NPmCv1oDUopToHK_r6H_Q215LW6TZKWGuc2QrhTIWSiQrG_lSmeV1RD6LfvPRnL_3qpd-89Fvm1X1z3c84PCT-iFgBeQZofUoHLH99_d_WXy-nmT4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660887979</pqid></control><display><type>article</type><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><source>Springer Nature</source><creator>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</creator><creatorcontrib>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</creatorcontrib><description>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the
1
H,
13
C and
15
N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</description><identifier>ISSN: 1874-2718</identifier><identifier>EISSN: 1874-270X</identifier><identifier>DOI: 10.1007/s12104-013-9536-9</identifier><identifier>PMID: 24395156</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Amino Acid Sequence ; Biochemistry ; Biological and Medical Physics ; Biophysics ; Cancer ; Drug Discovery ; Enzyme Inhibitors - pharmacology ; Glucuronidase - antagonists & inhibitors ; Glucuronidase - chemistry ; Heparan sulfate ; Humans ; Matrix ; Molecular Sequence Data ; NMR ; Nuclear magnetic resonance ; Nuclear Magnetic Resonance, Biomolecular ; Physics ; Physics and Astronomy ; Polymer Sciences ; Protein Structure, Secondary ; Protein Structure, Tertiary</subject><ispartof>Biomolecular NMR assignments, 2015-04, Vol.9 (1), p.15-19</ispartof><rights>Springer Science+Business Media Dordrecht 2014</rights><rights>Springer Science+Business Media Dordrecht 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24395156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><title>Biomolecular NMR assignments</title><addtitle>Biomol NMR Assign</addtitle><addtitle>Biomol NMR Assign</addtitle><description>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the
1
H,
13
C and
15
N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</description><subject>Amino Acid Sequence</subject><subject>Biochemistry</subject><subject>Biological and Medical Physics</subject><subject>Biophysics</subject><subject>Cancer</subject><subject>Drug Discovery</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Glucuronidase - antagonists & inhibitors</subject><subject>Glucuronidase - chemistry</subject><subject>Heparan sulfate</subject><subject>Humans</subject><subject>Matrix</subject><subject>Molecular Sequence Data</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Nuclear Magnetic Resonance, Biomolecular</subject><subject>Physics</subject><subject>Physics and Astronomy</subject><subject>Polymer Sciences</subject><subject>Protein Structure, Secondary</subject><subject>Protein Structure, Tertiary</subject><issn>1874-2718</issn><issn>1874-270X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU2LFDEQhoMo7rr6A7xIwIuX1lTSnY-jDOsHLHhR8NZk0pXpXqaTMdUR9t_b7ayLCJ4SyPO-Keph7CWItyCEeUcgQbSNANW4TunGPWKXYE3bSCO-P364g71gz4huhdBSSHjKLmSrXAedvmR3uxHnKfgjp3GKC_dE0yHNmBbiPg2cMOQ0-HLHaSk1LLUgz5EvI3KqpeSDX5APefZT4jEXPpR64MNEIf_E36E6TEhbZKyzT3zEky8-ecLn7En0R8IX9-cV-_bh-uvuU3Pz5ePn3fubJijXLo0Ug3G-w9AGES2Ci65VcR-1lNo4YRXovQ3OR9WBAY0yWqE0BtsZaWzr1BV7c-49lfyjIi39vI6Hx6NPmCv1oDUopToHK_r6H_Q215LW6TZKWGuc2QrhTIWSiQrG_lSmeV1RD6LfvPRnL_3qpd-89Fvm1X1z3c84PCT-iFgBeQZofUoHLH99_d_WXy-nmT4</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Mosulén, Silvia</creator><creator>Pineda-Lucena, Antonio</creator><creator>Carbajo, Rodrigo J.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><author>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amino Acid Sequence</topic><topic>Biochemistry</topic><topic>Biological and Medical Physics</topic><topic>Biophysics</topic><topic>Cancer</topic><topic>Drug Discovery</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Glucuronidase - antagonists & inhibitors</topic><topic>Glucuronidase - chemistry</topic><topic>Heparan sulfate</topic><topic>Humans</topic><topic>Matrix</topic><topic>Molecular Sequence Data</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Nuclear Magnetic Resonance, Biomolecular</topic><topic>Physics</topic><topic>Physics and Astronomy</topic><topic>Polymer Sciences</topic><topic>Protein Structure, Secondary</topic><topic>Protein Structure, Tertiary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Biomolecular NMR assignments</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mosulén, Silvia</au><au>Pineda-Lucena, Antonio</au><au>Carbajo, Rodrigo J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</atitle><jtitle>Biomolecular NMR assignments</jtitle><stitle>Biomol NMR Assign</stitle><addtitle>Biomol NMR Assign</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>9</volume><issue>1</issue><spage>15</spage><epage>19</epage><pages>15-19</pages><issn>1874-2718</issn><eissn>1874-270X</eissn><abstract>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the
1
H,
13
C and
15
N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>24395156</pmid><doi>10.1007/s12104-013-9536-9</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1874-2718 |
ispartof | Biomolecular NMR assignments, 2015-04, Vol.9 (1), p.15-19 |
issn | 1874-2718 1874-270X |
language | eng |
recordid | cdi_proquest_miscellaneous_1661333591 |
source | Springer Nature |
subjects | Amino Acid Sequence Biochemistry Biological and Medical Physics Biophysics Cancer Drug Discovery Enzyme Inhibitors - pharmacology Glucuronidase - antagonists & inhibitors Glucuronidase - chemistry Heparan sulfate Humans Matrix Molecular Sequence Data NMR Nuclear magnetic resonance Nuclear Magnetic Resonance, Biomolecular Physics Physics and Astronomy Polymer Sciences Protein Structure, Secondary Protein Structure, Tertiary |
title | Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemical%20shift%20assignments%20and%20secondary%20structure%20of%20the%20surrogate%20domain%20for%20drug%20discovery%20studies%20of%20human%20heparanase&rft.jtitle=Biomolecular%20NMR%20assignments&rft.au=Mosul%C3%A9n,%20Silvia&rft.date=2015-04-01&rft.volume=9&rft.issue=1&rft.spage=15&rft.epage=19&rft.pages=15-19&rft.issn=1874-2718&rft.eissn=1874-270X&rft_id=info:doi/10.1007/s12104-013-9536-9&rft_dat=%3Cproquest_cross%3E3615679541%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660887979&rft_id=info:pmid/24395156&rfr_iscdi=true |